Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Clin Cancer Res. 2022 Nov 1;28(21):4600-4602. doi: 10.1158/1078-0432.CCR-22-2104.
Through analysis of the cancer dependency map of CRISPR and short hairpin RNA datasets, the antiapoptotic BCL-XL was found to be a selective dependency in kidney cancer. Among kidney cancers, BCL-XL inhibition is most active in those with a mesenchymal gene signature, which portends a poor prognosis and response to current therapies. See related article by Grubb et al., p. 4689.
通过对 CRISPR 和短发夹 RNA 数据集的癌症依赖图谱进行分析,发现抗凋亡蛋白 BCL-XL 是肾癌的一个选择性依赖性。在肾癌中,具有间充质基因特征的肿瘤对 BCL-XL 抑制最为活跃,这预示着预后不良且对当前治疗方法无反应。详见 Grubb 等人的相关文章,第 4689 页。